GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Pulmonx Corporation
Pulmonx produces the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. Its stock price reflects the adoption of this revolutionary technology in medical practice. The chart is a growth story driven by a transformation in the standard of care for millions of patients.
Share prices of companies in the market segment - Therapeutic medical equipment
Pulmonx Corporation developed and markets the Zephyr valve, a minimally invasive device for treating patients with severe emphysema that helps improve lung function. We classified it in the "Therapeutic Medical Equipment" segment. The chart below shows the overall dynamics of the respiratory medical device sector.
Broad Market Index - GURU.Markets
Pulmonx is a medical device company that developed the Zephyr Valve, a minimally invasive device for the treatment of severe emphysema. Its innovative product makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Pulmonx compares to it.
Change in the price of a company, segment, and market as a whole per day
LUNG - Daily change in the company's share price Pulmonx Corporation
The daily price change of Pulmonx Corporation, a manufacturer of COPD treatment devices, reflects volatility in the MedTech sector. The metric demonstrates sensitivity to sales data, approvals, and clinical trial results.
Daily change in the price of a set of shares in a market segment - Therapeutic medical equipment
Pulmonx Corporation is a manufacturer of devices for the treatment of COPD. This chart illustrates the high volatility of the MedTech sector. Comparing it to LUNG's performance helps assess how sensitive its business is to sales data, approvals, and clinical trial results.
Daily change in the price of a broad market stock, index - GURU.Markets
Pulmonx produces medical devices for the treatment of chronic obstructive pulmonary disease (COPD). The medtech company's stock performance depends on the adoption of its technology in clinical practice. Such unique stories are part of a larger market whose overall volatility you can see.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Pulmonx Corporation
Pulmonx Corporation's year-over-year performance is a story of commercialization of its unique emphysema treatment device. Its market capitalization growth over the past 12 months reflects the growing number of hospitals using its Zephyr valves, which offer a minimally invasive alternative for patients with severe COPD.
Annual dynamics of market capitalization of the market segment - Therapeutic medical equipment
Pulmonx Corporation has revolutionized COPD treatment with its minimally invasive Zephyr valve. Its rapid growth is fueled by physician adoption of its technology. The chart below shows how its market dominance and efforts to expand insurance coverage are driving its outperformance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pulmonx, with its valves for treating COPD, is a growth story in medicine. Its stock price is driven not by the economy, but by the speed of adoption by doctors and the insurance system. The chart reflects the potential of this breakthrough technology in the vast respiratory market, regardless of the economic climate.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Pulmonx Corporation
Pulmonx manufactures and markets minimally invasive valves for the treatment of emphysema. Its monthly growth reflects the pace of adoption of this technology in hospitals worldwide. Quarterly reports of revenue growth and the number of procedures performed are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Therapeutic medical equipment
The market for medical devices for the treatment of chronic lung diseases is growing as the population ages. The dynamics of this sector, shown in the graph, reflect the demand for innovative therapeutic solutions. In this context, companies like Pulmonx are offering their products to improve patients' quality of life.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pulmonx, a manufacturer of medical devices for COPD treatment, is at the forefront of healthcare innovation. The company's stock can outperform the market thanks to the growing adoption of its technology. Its performance is driven more by medical advances than by the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Pulmonx Corporation
The weekly performance of Pulmonx, a manufacturer of valves for the treatment of emphysema, depends on the pace of their clinical adoption. News of insurance approvals, as well as data on the number of procedures performed, shape short-term investor sentiment.
Weekly dynamics of market capitalization of the market segment - Therapeutic medical equipment
Pulmonx shares, like those of the entire specialized medical equipment sector, respond to general hospital purchasing cycles. Hospital budgets and insurance reimbursement policies are drivers for everyone. The chart shows how this niche player stacks up against industry giants.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Pulmonx shares, like those of the entire specialized medical equipment sector, respond to general hospital purchasing cycles. Hospital budgets and insurance reimbursement policies are drivers for everyone. The chart shows how this niche player stacks up against industry giants.
Market capitalization of the company, segment and market as a whole
LUNG - Market capitalization of the company Pulmonx Corporation
Pulmonx's market capitalization is the financial valuation of the company that developed the Zephyr minimally invasive valve for the treatment of severe emphysema. The chart reflects both the uniqueness and effectiveness of its product and the challenges of its widespread adoption and commercialization. Its dynamics tell the story of the balance between changing standards of care and healthcare economics.
LUNG - Share of the company's market capitalization Pulmonx Corporation within the market segment - Therapeutic medical equipment
Pulmonx Corporation developed and commercialized the Zephyr Valve, a minimally invasive device for the treatment of severe emphysema. Its market share in the medical device sector reflects its leadership in this niche. The chart below shows the impact of this innovator, which helps patients breathe easier.
Market capitalization of the market segment - Therapeutic medical equipment
Pulmonx is the maker of the Zephyr valve for the treatment of severe emphysema. The chart below shows the overall market capitalization of the entire therapeutic device sector. Its growth reflects the search for new solutions for chronic diseases. Pulmonx's product offers a unique, minimally invasive procedure for improving breathing.
Market capitalization of all companies included in a broad market index - GURU.Markets
Chronic lung disease treatment is a large market, as shown in the chart. Pulmonx Corporation produces minimally invasive valves for the treatment of severe emphysema. Its market capitalization reflects the valuation of its unique product, which offers a new option for patients with limited treatment options.
Book value capitalization of the company, segment and market as a whole
LUNG - Book value capitalization of the company Pulmonx Corporation
Pulmonx is the material base for treating severe COPD. Its growth in book value reflects the expansion of its unique Zephyr valves, which are installed in the lungs without surgery. These are physical assets that help people breathe easier.
LUNG - Share of the company's book capitalization Pulmonx Corporation within the market segment - Therapeutic medical equipment
Pulmonx Corporation produces medical devices for the treatment of COPD. Its stake in the sector's assets includes the factories that manufacture its Zephyr valves. This physical base enables it to offer minimally invasive treatments to patients with severe emphysema worldwide.
Market segment balance sheet capitalization - Therapeutic medical equipment
Pulmonx Corporation produces medical devices for the treatment of COPD. Its business is moderately capital-intensive. The company requires manufacturing capacity to produce its Zephyr valves, but its core value also includes patents and clinical data. Compared to the medical device sector, this is a balanced asset model.
Book value of all companies included in the broad market index - GURU.Markets
Pulmonx's assets are not drugs, but rather the innovative Zephyr valves, which allow for the treatment of severe emphysema without surgery. The company's balance sheet reflects the value of this unique medical technology. The chart shows the capital behind this breakthrough solution for COPD patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Pulmonx Corporation
Pulmonx Corporation produces a medical device for the treatment of severe COPD. Its market capitalization is based on its proprietary technology and market growth potential. Investors are paying for a unique solution that can change the lives of millions of patients, creating a premium to its book value.
Market to book capitalization ratio in a market segment - Therapeutic medical equipment
Pulmonx manufactures and markets minimally invasive valves for the treatment of emphysema. The company's value lies in its unique, patented product. This chart shows the premium the market pays for its life-changing technology, not for the production lines that produce these valves.
Market to book capitalization ratio for the market as a whole
Pulmonx manufactures and markets minimally invasive valves for the treatment of emphysema. As a medical technology company, its valuation is based on its unique technology and patents. This chart demonstrates the high premium investors are paying for an innovative medical device capable of improving the quality of life for millions of patients.
Debts of the company, segment and market as a whole
LUNG - Company debts Pulmonx Corporation
Pulmonx Corporation produces a medical device for the treatment of severe COPD. Commercializing such a product requires significant investment in physician training, clinical trials to expand indications, and marketing. Debt financing is helping the company accelerate the global adoption of its technology.
Market segment debts - Therapeutic medical equipment
Pulmonx Corporation produces minimally invasive medical devices for the treatment of lung diseases. After commercialization, the company must invest in sales and marketing. This chart shows how Pulmonx finances its market expansion: through sales revenue or by raising debt capital to accelerate physician and patient engagement.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Pulmonx Corporation
Pulmonx Corporation produces medical devices for the treatment of lung diseases. This chart shows how the company uses debt to finance production, marketing, and further research. High debt loads in the medical device sector can be risky if competitors release more effective products or treatment standards change.
Market segment debt to market segment book capitalization - Therapeutic medical equipment
Pulmonx Corporation developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. This chart compares the company's debt used to commercialize this breakthrough technology to the overall market capitalization of the entire therapeutic medical device sector. It reflects the financial implications of implementing a new standard of care.
Debt to book value of all companies in the market
Pulmonx Corporation manufactures and markets minimally invasive medical devices for the treatment of lung diseases. The company's growth requires investment in marketing and production. The chart shows how actively Pulmonx uses debt capital to scale its business and how this strategy compares to the overall medical device sector, with its stable demand.
P/E of the company, segment and market as a whole
P/E - Pulmonx Corporation
For Pulmonx, a manufacturer of medical devices for COPD treatment, this chart is an indicator of the adoption of this new technology. Investors' high profit estimates indicate their belief that their valves will become standard treatment for many patients. The trend shows how quickly doctors and hospitals are adopting this innovative, albeit expensive, method.
P/E of the market segment - Therapeutic medical equipment
This chart shows the average valuation for medical device manufacturers—the benchmark for Pulmonx. Comparing this company's valuation to the broader industry average helps us understand the premium investors are willing to pay for its innovative COPD treatment device and its potential to become a standard in its field.
P/E of the market as a whole
Pulmonx has developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. This breakthrough technology is changing the standard of care for a specific group of patients. This chart reflects sentiment in the medical technology sector and helps understand how the pace of clinical adoption of this new technology impacts Pulmonx's growth and valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Pulmonx Corporation
Pulmonx Corporation manufactures and markets the Zephyr Valve, a minimally invasive device for treating patients with severe emphysema. The company's future growth depends on wider adoption of this procedure by physicians and its coverage by insurance companies. This chart shows whether analysts believe this technology has the potential to become a standard of care.
%20P%2FE%20Pulmonx%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Pulmonx-Corporation&v=1772513783122 "Chart of the company's future (projected) P/E Pulmonx Corporation")
Future (projected) P/E of the market segment - Therapeutic medical equipment
Pulmonx Corporation developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. The chart shows how the company's revenue forecast compares to the medical device industry average. This reflects the market's perception of its unique, treatment-changing product and its potential for global adoption.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Therapeutic-medical-equipment&v=1772513783143 "Future (projected) P/E graph of the market segment - Therapeutic medical equipment")
Future (projected) P/E of the market as a whole
Pulmonx Corporation has developed and markets the Zephyr valve for the treatment of severe emphysema. This chart reflects the overall sentiment in the healthcare sector. For Pulmonx, the importance of economics is less about the speed of adoption of their technology by doctors and reimbursement from insurance companies. This is a growth story driven by a shift in the standard of care.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513783160 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Pulmonx Corporation
Pulmonx Corporation has developed and commercialized the Zephyr Valve, a minimally invasive device for treating patients with severe emphysema. This chart shows how this medical innovation, which improves patients' quality of life, impacts financial performance. Profitability depends on the widespread adoption of the technology and insurance reimbursement.
Profit of companies in the market segment - Therapeutic medical equipment
Pulmonx Corporation has developed and markets the Zephyr valve, a minimally invasive device for treating patients with severe emphysema. This device is transforming the treatment of chronic obstructive pulmonary disease. This chart shows the overall profitability of the medical device sector, demonstrating how innovative therapeutic devices are finding their niche in the market.
Overall market profit
Pulmonx Corporation offers minimally invasive treatments for patients with severe emphysema. Demand for its products is driven by medical needs, making it less dependent on economic cycles. However, the pace of adoption of new medical technologies may depend on hospital budgets, which are more stable during periods of overall economic growth.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Pulmonx Corporation
Pulmonx has developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. The company's future depends on the widespread adoption of this procedure by physicians. This chart shows analysts' forecasts for global sales growth for this innovative medical device.
%20profit%20of%20the%20company%20Pulmonx%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Pulmonx-Corporation&v=1772513783191 "Graph of future (projected) profit of the company Pulmonx Corporation")
Future (predicted) profit of companies in the market segment - Therapeutic medical equipment
Pulmonx Corporation has developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. This chart shows forecasts for the medical device sector. Pulmonx's profitability depends on the widespread adoption of its technology in clinical practice, insurance reimbursement, and convincing physicians of its advantages over traditional treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Therapeutic-medical-equipment&v=1772513783195 "Graph of future (predicted) profits of companies in a market segment - Therapeutic medical equipment")
Future (predicted) profit of the market as a whole
Pulmonx Corporation manufactures and markets minimally invasive devices for the treatment of severe emphysema. Demand for its products depends on healthcare system budgets and patient affordability. This graph, showing corporate profit projections, is an indicator of overall economic health, which impacts healthcare funding and access to advanced treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513783198 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Pulmonx Corporation
Pulmonx Corporation developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. This chart shows how highly investors value its revenue, reflecting their belief in the growing adoption of this unique technology and the improvement in the quality of life of COPD patients.
P/S market segment - Therapeutic medical equipment
Pulmonx Corporation has developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. The company's revenue growth depends on the adoption of this technology in clinical practice worldwide. This chart shows the average rating for medical device manufacturers, helping to understand how the market values Pulmonx's unique and breakthrough solution for patients.
P/S of the market as a whole
Pulmonx Corporation developed and markets the Zephyr valve, a minimally invasive device for treating patients with severe emphysema. It is an innovative product in pulmonology. This chart shows the premium investors are willing to pay for the company's revenue, which offers a unique and effective solution for a large group of patients.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Pulmonx Corporation
Pulmonx Corporation manufactures and markets the Zephyr Valve, a minimally invasive device for treating patients with severe emphysema. This chart shows how investors view the company's future revenue. It reflects expectations for sales growth through geographic expansion, insurance coverage, and acceptance by the medical community.
%20P%2FS%20Pulmonx%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Pulmonx-Corporation&v=1772513783270 "The graph of the company's future (projected) P/S Pulmonx Corporation")
Future (projected) P/S of the market segment - Therapeutic medical equipment
Pulmonx manufactures and markets a minimally invasive device for treating patients with severe emphysema. This chart compares the company's estimated future sales with its industry. It reflects the market's assessment of the clinical penetration and commercial success of this innovative technology.
%20P%2FS%20market%20segment%20graph%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Therapeutic-medical-equipment&v=1772513783283 "Future (projected) P/S market segment graph - Therapeutic medical equipment")
Future (projected) P/S of the market as a whole
Pulmonx Corporation has developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. The optimism expressed by this indicator is often fueled by medical breakthroughs. Pulmonx's solution is changing the standard of care and exemplifies how innovative medical devices can improve quality of life and generate new revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513783299 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Pulmonx Corporation
Pulmonx Corporation manufactures and markets the Zephyr Valve, a minimally invasive device for the treatment of severe emphysema. Revenue, shown in this chart, is generated from sales of these valves to hospitals. This growth reflects the increasing number of patients undergoing this procedure and the expansion of sales geographies.
Sales of companies in the market segment - Therapeutic medical equipment
Pulmonx Corporation has developed and commercialized the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. Their technology offers new hope for patients with COPD. This graph illustrates the growth of the medical device market, where breakthrough products like Pulmonx's are creating new treatment standards and entire market segments.
Overall market sales
Pulmonx Corporation produces minimally invasive devices for the treatment of severe emphysema. The implementation of its technology depends on hospital budgets and insurance coverage. The increase in overall economic revenue, reflected in this graph, improves the financial health of the healthcare system. This allows clinics to more actively implement innovative treatments that improve patients' quality of life.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Pulmonx Corporation
Pulmonx Corporation has developed and markets the Zephyr valve, a minimally invasive device for treating patients with severe emphysema. This chart shows analysts' assessments of the pace of adoption of this breakthrough technology in medical practice and its potential to improve the quality of life for millions of patients with chronic lung disease.
%20sales%20of%20the%20company%20Pulmonx%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Pulmonx-Corporation&v=1772513783365 "Schedule of future (projected) sales of the company Pulmonx Corporation")
Future (projected) sales of companies in the market segment - Therapeutic medical equipment
Pulmonx Corporation has developed and commercialized the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. This chart shows forecasts for the therapeutic device sector, helping to assess the significant contribution this technology, offering new hope for millions of COPD patients, can make to the growth of this market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Therapeutic-medical-equipment&v=1772513783391 "Schedule of future (projected) sales of companies in the market segment - Therapeutic medical equipment")
Future (projected) sales of the market as a whole
Pulmonx, a manufacturer of COPD treatment devices, sees this chart as an indicator of access to specialized medical care. The economic growth reflected here means more patients have insurance, and hospitals can afford to implement new, minimally invasive technologies that improve patients' quality of life.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513783431 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Pulmonx Corporation
Pulmonx Corporation manufactures and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. The company's profitability depends on the acceptance of this technology by physicians and hospitals, as well as reimbursement from insurance companies. This chart shows how successfully the commercialization of this unique medical device is translating into net profit.
Market segment marginality - Therapeutic medical equipment
Pulmonx Corporation manufactures and markets minimally invasive devices for the treatment of severe emphysema. Profitability in the medical device sector depends on product innovation and effective commercialization. The chart shows how successfully the company converts its unique technology into profit compared to other medical device manufacturers.
Market marginality as a whole
Pulmonx Corporation has developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. Despite its overall profitability, Pulmonx is operating in a niche with an unmet medical need. Their profitability depends on the widespread adoption of their technology and insurance reimbursement.
Employees in the company, segment and market as a whole
Number of employees in the company Pulmonx Corporation
Pulmonx Corporation helps patients with severe lung diseases breathe easier with its innovative Zephyr valve. This chart shows the size of its sales and research teams. The growth in staff, particularly in the sales department, reflects efforts to expand the use of this life-saving technology.
Share of the company's employees Pulmonx Corporation within the market segment - Therapeutic medical equipment
Pulmonx Corporation developed and commercialized the Zephyr valve, a revolutionary device for the treatment of severe emphysema. This chart shows the percentage of specialists—from engineers to clinicians—in the pulmonology therapeutic medical device niche that Pulmonx attracts. This is a measure of its leadership and scale in changing the standard of COPD treatment.
Number of employees in the market segment - Therapeutic medical equipment
Pulmonx Corporation has developed and commercialized a minimally invasive device for the treatment of severe emphysema. Its success depends on a commercial team that trains physicians. This chart shows how the company is expanding its market presence. Headcount growth, particularly in sales, is an indicator of increasing procedure volume and geographic expansion.
Number of employees in the market as a whole
Pulmonx Corporation produces medical devices for the treatment of lung diseases. The medical device sector is dependent on demographics and healthcare systems. The employment growth seen in this graph may correlate with increased insurance coverage, which increases access to treatments and demand for Pulmonx products.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Pulmonx Corporation (LUNG)
Pulmonx produces medical equipment that combines R&D and manufacturing. This metric reflects the balance between the value of patents and the efficiency of production lines. Its dynamics on a graph can show how the company's focus is shifting from development to scaling sales.
%20of%20the%20company%20Pulmonx%20Corporation%20(LUNG)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Pulmonx-Corporation-LUNG&v=1772513783599 "Chart of market capitalization per employee (in thousands of dollars) of the company Pulmonx Corporation (LUNG)")
Market capitalization per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
Pulmonx Corporation offers minimally invasive treatments for patients with lung diseases. In the medical device sector, this metric reflects how the market perceives the commercial potential and uniqueness of the company's technology. The graph helps understand whether its business model is more or less capital-intensive per employee compared to its competitors.
%20by%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Therapeutic-medical-equipment&v=1772513783610 "Market capitalization per employee (in thousands of dollars) by market segment - Therapeutic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
Pulmonx Corporation developed and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. It is a medical technology company with a commercial product. This chart shows how the market values a business where a unique, patented device and the team promoting it generate high value per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513783628 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Pulmonx Corporation (LUNG)
Pulmonx manufactures and markets a medical device (the Zephyr valve) for the treatment of severe emphysema. It is a groundbreaking therapeutic product. This chart shows how successfully the company is commercializing its device. It reflects how much profit each employee (salesperson, engineer) generates from sales of this high-margin product.
%20Chart%20Pulmonx%20Corporation%20(LUNG)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Pulmonx-Corporation-LUNG&v=1772513783643 "Company Profit Per Employee (in thousands of dollars) Chart Pulmonx Corporation (LUNG)")
Profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
Pulmonx (LUNG) manufactures and markets a medical device (the Zephyr valve) for the treatment of severe emphysema. It is a medical device business. This chart shows how effectively the company is scaling sales of its innovative product. It reflects commercial return (revenue) per employee, including sales, clinical support, and manufacturing.
%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Therapeutic-medical-equipment&v=1772513783661 "Chart of profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
Pulmonx Corporation manufactures and sells a medical device (the Zephyr valve) for the treatment of emphysema. This is already at the commercial stage, not pure R&D. This chart shows how effectively the company is scaling sales. Profit per employee here depends on the balance between production costs, the cost of the sales team (which trains doctors), and the price of the device itself.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513783673 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Pulmonx Corporation (LUNG)
Pulmonx Corporation produces and markets a minimally invasive device for the treatment of severe emphysema. This chart shows how well their product is being adopted by the medical community. Growing revenue per employee means more physicians are using their technology, and their sales team is effectively expanding their market reach.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Pulmonx-Corporation-LUNG&v=1772513783690 "Sales chart per company employee Pulmonx Corporation (LUNG)")
Sales per employee in the market segment - Therapeutic medical equipment
Pulmonx manufactures and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. It is a breakthrough product in pulmonology. This chart shows the average revenue per employee in the sector. It is critical for assessing how effectively Pulmonx's commercial team trains physicians and markets its innovative device compared to other MedTech companies.
Sales per employee for the market as a whole
Pulmonx Corporation (LUNG) manufactures and markets the Zephyr valve, a minimally invasive device for the treatment of severe emphysema. It's a life-changing medical device for patients. This chart shows how successfully their commercial team (sales and marketing) is implementing this technology in hospitals and generating revenue per employee.
Short shares by company, segment and market as a whole
Shares shorted by company Pulmonx Corporation (LUNG)
Pulmonx revolutionized COPD treatment with its Zephyr valve, which is implanted minimally invasively. Despite approval, adoption is slow. This chart shows the number of investors betting the company will fail to convince doctors and insurers to widely use the procedure, limiting its market potential.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Pulmonx-Corporation-LUNG&v=1772513783775 "Short Shares Chart for the Company Pulmonx Corporation (LUNG)")
Shares shorted by market segment - Therapeutic medical equipment
Pulmonx revolutionized COPD treatment with its Zephyr valve, which improves breathing without major surgery. This chart shows bearish sentiment in the sector. If it rises, investors expect hospitals to cut spending on new technologies or insurers to tighten reimbursement rules for the entire industry.
Shares shorted by the overall market
Pulmonx produces medical devices (valves) for the treatment of emphysema. These devices improve quality of life. This chart reflects the overall market pessimism. When investors fear a recession, they expect hospitals and patients to postpone elective, non-emergency surgeries to save money, which will hurt Pulmonx's sales.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Pulmonx Corporation (LUNG)
This oscillator shows how the market is pricing in the adoption of Pulmonx's technology. The company produces Zephyr valves, a non-surgical treatment for severe emphysema (COPD). When Pulmonx reports accelerating surgeon adoption or expanding insurance coverage, investors tend to overvalue the stock (above 70). Slow adoption or reimbursement issues lead to oversold prices (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Pulmonx-Corporation-LUNG&v=1772513783792 "RSI 14 indicator chart for the company's stock Pulmonx Corporation (LUNG)")
RSI 14 Market Segment - Therapeutic medical equipment
Pulmonx (LUNG) is "breathing" for the lungs. Their specialty is *endobronchial valves* (Zephyr Valve), a *minimally invasive* treatment for *emphysema*. The "Therapeutic medical equipment" (medtech) sector thrives on R&D. RSI_14_Seg shows whether the *entire* sector is "overbought." This helps differentiate: is LUNG's growth a niche or a general "overheating"?
RSI 14 for the overall market
For Pulmonx (LUNG), whose devices treat COPD, this chart is an indicator of elective surgeries. During periods of euphoria and stability, patients confidently undergo expensive elective surgeries. During periods of market panic and rising unemployment, people, fearing loss of insurance, postpone "non-urgent" surgeries.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LUNG (Pulmonx Corporation)
Pulmonx (LUNG) produces the Zephyr valve, a minimally invasive device for treating patients with severe emphysema (COPD). This chart shows analysts' average 12-month forecast. It reflects their expectations for the pace of clinical adoption of this technology and the expansion of insurance coverage, which are key to growth.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LUNG-Pulmonx-Corporation&v=1772513783850 "A chart showing analyst consensus forecasts for the expected stock price. LUNG (Pulmonx Corporation)")
The difference between the consensus estimate and the actual stock price LUNG (Pulmonx Corporation)
Pulmonx (LUNG) is a medical technology company that created the Zephyr valve, a minimally invasive device for the treatment of severe emphysema (COPD). This chart shows the valuation of their technology. It measures the gap between the price and the consensus target, reflecting whether analysts believe their valve will become a standard of care and be widely adopted by physicians.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LUNG-Pulmonx-Corporation&v=1772513783865 "A chart showing the difference between the consensus forecast and the actual stock price. LUNG (Pulmonx Corporation)")
Analyst consensus forecast for stock prices by market segment - Therapeutic medical equipment
Pulmonx is changing the way COPD is treated. Its flagship product, the Zephyr valve, is a minimally invasive device for the treatment of emphysema. This chart reflects analysts' overall expectations for the entire therapeutic medical device sector, demonstrating whether experts believe demand for innovative MedTech will grow.
Analysts' consensus forecast for the overall market share price
Pulmonx produces the Zephyr valve for emphysema treatment—a premium, non-emergency procedure. This chart, showing the collective market forecast, is key. When analysts are optimistic, employment is high (people have insurance), and consumers are willing to undergo elective procedures. During a recession (pessimism), these procedures are often postponed.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Pulmonx Corporation
Pulmonx is a MedTech company that helps people with severe COPD (emphysema) breathe. Their flagship product is the Zephyr valve, a minimally invasive device (implant) that shuts off diseased areas of the lung. This chart is a summary indicator of their commercialization, reflecting the rate of hospital adoption of their breakthrough technology and their ability to receive reimbursement from insurance companies.
AKIMA Market Segment Index - Therapeutic medical equipment
Pulmonx (LUNG) is changing the treatment of severe COPD (chronic obstructive pulmonary disease). Their Zephyr valve is a minimally invasive device that helps patients breathe. The graph shows the average index for the segment. It helps assess how successfully Pulmonx is commercializing its unique technology compared to the average in the therapeutic medical device sector.
The AKIM Index for the overall market
Pulmonx is a medtech company that produces the Zephyr valve for the treatment of severe emphysema. It's a minimally invasive alternative to surgery. This chart, which reflects the market average, provides context. It helps us assess how this commercialization story in respiratory medicine compares to overall macroeconomic trends and physician adoption.
